hotspot -WSS

hotspot

author：focus 2025-08-12 09:11:06 - browse：4244

Without question, the new federal law banning surprise billing is achieving its goal of protecting patients from enormous medical bills. But in doing so, the measure, which was initially projected to lower federal spending, appears to be raising costs elsewhere.

The Biden administration’s new progress report on the process for arbitrating disagreements between insurance companies and providers, which covers the first six months of 2023, shows that in over 80% of payment disputes, the arbiter settled on an amount that was more than the median in-network rate for that service. In other words, insurers were ordered to pay more to an out-of-network provider than they’d pay to a contracted one. Not only that, the sheer volume of disputes means the three federal agencies that run the program are devoting much more time to it than expected.

“It raises concerns for folks that envisioned the arbitration process as helping to moderate costs rather than be a tool these companies can leverage to obtain even higher payments,” said Zachary Baron, the director of Georgetown University’s Health Policy and Law Initiative.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Key House Republican on health care plans exit from Congress

WSS

Living organ donors deserve priority status for transplants

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Medicare Advantage proposed rates disappoint insurers

The Readout: Gilead, Bernie Sanders, and other pharma news

Biden administration plans revamp of organ transplant system

knowledge

hotspot

focus

Guidelines to prevent youth baseball injuries need more muscle

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

After affirmative action ruling, medical educators look to 'holistic review'

Millions may soon lose Medicaid when they don't have to

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare threatens to cut off funding for HCA's Mission hospital

How to save PrEP access — and even expand it

Readout LOUD podcast: How biotech is using artificial intelligence

Cancer drug shortages should be causing more outrage

Medical mystery: When a cough is not just a cough

focus

Living organ donors deserve priority status for transplants

The Readout: Gilead, Bernie Sanders, and other pharma news

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Gilead might be held responsible for not developing a drug

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Sea level rise could wash away turtle breeding grounds around the world, researchers say

knowledge

focus

entertainment

knowledge